RxDoctor Payments Data

Haley Southwick

Primary Care · Las Vegas, NVNPI 1598402760

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.

$1,327in general payments, 2019–2025

Across 51 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$271
  • Novo Nordisk$211
  • Daiichi Sankyo Inc.$144
  • Exact Sciences$128
  • AstraZeneca$128
  • Amgen$115
  • plus $329 from 6 others

What the payments were for

  • Food & beverage$1,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,327 in reported general payments places this provider in the 75th percentile of 81 primary care providers in Nevada.

See all primary care providers in Nevada

Medicare billing

Part B allowed, 2024
$14,257
Medicare patients
49
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$23,216
Levothyroxine Sodium52$355
Atorvastatin Calcium43$342
Omeprazole15$340
Losartan Potassium32$301
Amlodipine Besylate51$259
Simvastatin20$250
Escitalopram Oxalate12$236
Gabapentin21$225
Lisinopril30$224
Fluticasone Propionate20$221
Atenolol12$121
Hydrochlorothiazide19$79
Metformin Hcl15$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$271$23,21618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 primary care providers in Nevada.

Other primary care in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →